Sphingolipid metabolism and drug resistance in ovarian cancer  

作　　者：Kelly M.Kreitzburg Robert C.A.Mvan Waardenburg Karina J.Yoon 

机构地区：[1]Department of Pharmacology and Toxicology,University of Alabama at Birmingham,Birmingham,AL 35294,USA

出　　处：《Cancer Drug Resistance》2018年第3期181-197,共17页癌症耐药（英文）

基　　金：Waardenburg RCAM is supported by DoD OCRP pilot grant W81XWH-15-1-0198;This work was supported by Faculty Development Grant from University of Alabama at Birmingham,Comprehensive Cancer Center(P30 CA013148).

摘　　要：Despite progress in understanding molecular aberrations that contribute to the development and progression of ovarian cancer,virtually all patients succumb to drug resistant disease at relapse.Emerging data implicate bioactive sphingolipids and regulation of sphingolipid metabolism as components of response to chemotherapy or development of resistance.Increases in cytosolic ceramide induce apoptosis in response to therapy with multiple classes of chemotherapeutic agents.Aberrations in sphingolipid metabolism that accelerate the catabolism of ceramide or that prevent the production and accumulation of ceramide contribute to resistance to standard of care platinum-and taxane-based agents.The aim of this review is to highlight current literature and research investigating the influence of the sphingolipids and enzymes that comprise the sphingosine-1-phosphate pathway on the progression of ovarian cancer.The focus of the review is on the utility of sphingolipid-centric therapeutics as a mechanism to circumvent drug resistance in this tumor type.

关 键 词：Ovarian cancer DRUG-RESISTANCE CERAMIDE sphingosine-1-phosphate sphingolipid metabolism 

分 类 号：R73[医药卫生—肿瘤]